Sodium/glucose cotransporter 2/ja - Revision history

Fire at 23:59, 18 February 2024

2024-02-18T23:59:17Z

← Older revision		Revision as of 08:59, 19 February 2024
Line 37:		Line 37:
	{{refend}}		{{refend}}

	{{Solute carrier family\|bg\|bg0}}		{{Solute carrier family/ja\|bg\|bg0}}
	{{Sodium-glucose transporter modulators/ja}}		{{Sodium-glucose transporter modulators/ja}}

	[[Category:Solute carrier family]]		[[Category:Solute carrier family]]
	[[Category:Genes mutated in mice]]		[[Category:Genes mutated in mice]]

Fire: Created page with "Category:Solute carrier family Category:Genes mutated in mice"

2024-02-18T11:34:40Z

Created page with "Category:Solute carrier family Category:Genes mutated in mice"

← Older revision		Revision as of 20:34, 18 February 2024
Line 26:		Line 26:
	{{reflist\|33em}}		{{reflist\|33em}}

	~~<div lang~~=~~"en" dir~~=~~"ltr" class="mw-content-ltr">~~		== さらに読む ==
	~~== Further reading~~ ==
	{{refbegin\|33em}}		{{refbegin\|33em}}
	* {{cite journal \| vauthors = van den Heuvel LP, Assink K, Willemsen M, Monnens L \| title = Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) \| journal = Human Genetics \| volume = 111 \| issue = 6 \| pages = 544–7 \| date = Dec 2002 \| pmid = 12436245 \| doi = 10.1007/s00439-002-0820-5 \| s2cid = 28089635 }}		* {{cite journal \| vauthors = van den Heuvel LP, Assink K, Willemsen M, Monnens L \| title = Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) \| journal = Human Genetics \| volume = 111 \| issue = 6 \| pages = 544–7 \| date = Dec 2002 \| pmid = 12436245 \| doi = 10.1007/s00439-002-0820-5 \| s2cid = 28089635 }}
Line 37:		Line 36:
	* {{cite journal \| vauthors = Castaneda F, Burse A, Boland W, Kinne RK \| title = Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes \| journal = International Journal of Medical Sciences \| volume = 4 \| issue = 3 \| pages = 131–9 \| year = 2007 \| pmid = 17505558 \| pmc = 1868657 \| doi = 10.7150/ijms.4.131 }}		* {{cite journal \| vauthors = Castaneda F, Burse A, Boland W, Kinne RK \| title = Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes \| journal = International Journal of Medical Sciences \| volume = 4 \| issue = 3 \| pages = 131–9 \| year = 2007 \| pmid = 17505558 \| pmc = 1868657 \| doi = 10.7150/ijms.4.131 }}
	{{refend}}		{{refend}}
	~~</div>~~

	~~<div lang="en" dir="ltr" class="mw-content-ltr">~~
	{{Solute carrier family\|bg\|bg0}}		{{Solute carrier family\|bg\|bg0}}
	{{Sodium-glucose transporter modulators}}		{{Sodium-glucose transporter modulators/ja}}
	~~{{二次利用\|date=18 December 2023}}~~
	~~</div>~~

	~~<div lang="en" dir="ltr" class="mw-content-ltr">~~
	[[Category:Solute carrier family]]		[[Category:Solute carrier family]]
	[[Category:Genes mutated in mice]]		[[Category:Genes mutated in mice]]
	~~</div>~~

Fire: Created page with "== こちらも参照 == * SGLTファミリー * グリフロジンの発見と開発 * フロリジン — SGLT1およびSGLT2の競合的阻害薬である。"

2024-02-18T11:33:58Z

Created page with "== こちらも参照 == * SGLTファミリー * グリフロジンの発見と開発 * フロリジン — SGLT1およびSGLT2の競合的阻害薬である。"

← Older revision		Revision as of 20:33, 18 February 2024
Line 18:		Line 18:
	この遺伝子の変異は[[renal glycosuria/ja\|腎性糖尿症]]とも関連している。		この遺伝子の変異は[[renal glycosuria/ja\|腎性糖尿症]]とも関連している。

	~~<div lang~~=~~"en" dir~~=~~"ltr" class="mw-content-ltr">~~		== こちらも参照 ==
	~~== See also~~ ==		* [[SGLT/ja\|SGLT]]ファミリー
	* [[SGLT]] ~~Family~~		* [[Discovery and development of gliflozins/ja\|グリフロジンの発見と開発]]
	* [[Discovery and development of gliflozins]]		* [[Phlorizin/ja\|フロリジン]] — [[SLC5A1/ja\|SGLT1]]および[[SGLT2/ja\|SGLT2]]の競合的阻害薬である。
	* [[Phlorizin]] — ~~a competitive inhibitor of~~ [[SLC5A1\|SGLT1]] ~~and~~ [[SGLT2]]
	~~</div>~~

	~~<div lang="en" dir="ltr" class="mw-content-ltr">~~
	== References ==		== References ==
	{{reflist\|33em}}		{{reflist\|33em}}
	~~</div>~~

	<div lang="en" dir="ltr" class="mw-content-ltr">		<div lang="en" dir="ltr" class="mw-content-ltr">

Fire: Created page with "この遺伝子の変異は腎性糖尿症とも関連している。"

2024-02-18T11:33:00Z

Created page with "この遺伝子の変異は腎性糖尿症とも関連している。"

← Older revision		Revision as of 20:33, 18 February 2024
Line 16:		Line 16:
	{{Anchor\|Clinical significance}}		{{Anchor\|Clinical significance}}

	~~<div lang="en" dir="ltr" class="mw-content-ltr">~~		この遺伝子の変異は[[renal glycosuria/ja\|腎性糖尿症]]とも関連している。
	~~Mutations in this gene are also associated with~~ [[renal glycosuria]].
	~~</div>~~

	<div lang="en" dir="ltr" class="mw-content-ltr">		<div lang="en" dir="ltr" class="mw-content-ltr">

Fire: Created page with "== 糖尿病治療薬SGLT2阻害薬 == {{Anchor|SGLT2 inhibitors for diabetes}} {{Main/ja|SGLT2 inhibitor/ja}} SGLT2阻害薬は、グリフロジンまたはフロジンとも呼ばれる。SGLT2阻害薬は血糖値を低下させるため、2型糖尿病の治療に使用される可能性がある。グリフロジンは血糖コントロールを高めるだけでなく、体重や収縮期およ..."

2024-02-18T11:11:57Z

Created page with "== 糖尿病治療薬SGLT2阻害薬 == {{Anchor|SGLT2 inhibitors for diabetes}} {{Main/ja|SGLT2 inhibitor/ja}} SGLT2阻害薬は、グリフロジンまたはフロジンとも呼ばれる。SGLT2阻害薬は血糖値を低下させるため、2型糖尿病の治療に使用される可能性がある。グリフロジンは血糖コントロールを高めるだけでなく、体重や収縮期およ..."

← Older revision		Revision as of 20:11, 18 February 2024
Line 8:		Line 8:
	SGLT2は、ナトリウム依存性[[glucose/ja\|グルコース]]輸送タンパク質である[[sodium-glucose transport proteins/ja\|ナトリウムグルコース共輸送体ファミリー]]のメンバーである。SGLT2は、腎臓におけるグルコースの[[reabsorption/ja\|再吸収]]に関与する主要な共輸送体である。 SGLT2は初期の[[proximal tubule/ja\|近位尿細管]]に存在し、腎臓[[Glomerulus (kidney)/ja\|糸球体]]で濾過されるグルコースの80～90％の再吸収を担っている。残りのグルコース吸収のほとんどは、近位尿細管のより遠位部にある[[sodium/glucose cotransporter 1/ja\|ナトリウム/グルコース共輸送体1]]（SGLT1）によるものである。		SGLT2は、ナトリウム依存性[[glucose/ja\|グルコース]]輸送タンパク質である[[sodium-glucose transport proteins/ja\|ナトリウムグルコース共輸送体ファミリー]]のメンバーである。SGLT2は、腎臓におけるグルコースの[[reabsorption/ja\|再吸収]]に関与する主要な共輸送体である。 SGLT2は初期の[[proximal tubule/ja\|近位尿細管]]に存在し、腎臓[[Glomerulus (kidney)/ja\|糸球体]]で濾過されるグルコースの80～90％の再吸収を担っている。残りのグルコース吸収のほとんどは、近位尿細管のより遠位部にある[[sodium/glucose cotransporter 1/ja\|ナトリウム/グルコース共輸送体1]]（SGLT1）によるものである。

	~~<div lang~~=~~"en" dir~~=~~"ltr" class~~=~~"mw-content-ltr">~~		== 糖尿病治療薬SGLT2阻害薬 ==
	== SGLT2 inhibitors for diabetes ==		{{Anchor\|SGLT2 inhibitors for diabetes}}
	{{Main\|SGLT2 inhibitor}}		{{Main/ja\|SGLT2 inhibitor/ja}}
	[[SGLT2 inhibitor]]~~s are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of~~ [[type 2 diabetes]]~~. Gliflozins enhance glycemic control as well as reduce~~ [[Human body weight\|~~body weight~~]] ~~and systolic and diastolic~~ [[blood pressure]]~~. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic~~ [[ketoacidosis]]~~. Other side effects of gliflozins include increased risk of Fournier gangrene~~		[[SGLT2 inhibitor/ja\|SGLT2阻害薬]]は、グリフロジンまたはフロジンとも呼ばれる。SGLT2阻害薬は血糖値を低下させるため、[[type 2 diabetes/ja\|2型糖尿病]]の治療に使用される可能性がある。グリフロジンは血糖コントロールを高めるだけでなく、[[Human body weight/ja\|体重]]や収縮期および拡張期[[blood pressure/ja\|血圧]]を低下させる。グリフロジンのカナグリフロジン、ダパグリフロジン、エンパグリフロジンは、優血[[ketoacidosis/ja\|ケトアシドーシス]]を引き起こす可能性がある。グリフロジンのその他の副作用には、フルニエ壊疽のリスク増大が含まれる
	~~</div>~~

	~~<div lang~~=~~"en" dir~~=~~"ltr" class~~=~~"mw-content-ltr">~~		== 臨床的意義 ==
	== Clinical significance ==		{{Anchor\|Clinical significance}}
	~~</div>~~

	<div lang="en" dir="ltr" class="mw-content-ltr">		<div lang="en" dir="ltr" class="mw-content-ltr">

Fire: Created page with "== 機能 == {{Anchor|Function}} SGLT2は、ナトリウム依存性グルコース輸送タンパク質であるナトリウムグルコース共輸送体ファミリーのメンバーである。SGLT2は、腎臓におけるグルコースの再吸収に関与する主要な共輸送体である。 SGLT2は初期の近位尿細管に存在し、腎臓Glomerulus (kidney)..."

2024-02-18T11:08:08Z

Created page with "== 機能 == {{Anchor|Function}} SGLT2は、ナトリウム依存性グルコース輸送タンパク質であるナトリウムグルコース共輸送体ファミリーのメンバーである。SGLT2は、腎臓におけるグルコースの再吸収に関与する主要な共輸送体である。 SGLT2は初期の近位尿細管に存在し、腎臓Glomerulus (kidney)..."

← Older revision		Revision as of 20:08, 18 February 2024
Line 4:		Line 4:
	'''ナトリウム/グルコース共輸送体2'''（'''sodium/glucose cotransporter 2'''）（SGLT2）は、ヒトでは{{gene\|SLC5A2}}によってコードされる[[protein/ja\|タンパク質]]である。		'''ナトリウム/グルコース共輸送体2'''（'''sodium/glucose cotransporter 2'''）（SGLT2）は、ヒトでは{{gene\|SLC5A2}}によってコードされる[[protein/ja\|タンパク質]]である。

	~~<div lang~~=~~"en" dir~~=~~"ltr" class~~=~~"mw-content-ltr">~~		== 機能 ==
	== Function ==		{{Anchor\|Function}}
	~~SGLT2 is a member of the~~ [[~~sodium-~~glucose ~~transport proteins~~\|~~sodium glucose cotransporter family~~]]~~, which are~~ sodium-~~dependent [[~~glucose]] ~~transport proteins. SGLT2 is the major cotransporter involved in glucose~~ [[reabsorption]] ~~in the kidney. SGLT2 is located in the early~~ [[proximal tubule]]~~, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney~~ [[Glomerulus (kidney)\|~~glomerulus~~]]~~. Most of the remaining glucose absorption is by~~ [[sodium/glucose cotransporter 1]] ~~(SGLT1) in more distal sections of the proximal tubule.~~		SGLT2は、ナトリウム依存性[[glucose/ja\|グルコース]]輸送タンパク質である[[sodium-glucose transport proteins/ja\|ナトリウムグルコース共輸送体ファミリー]]のメンバーである。SGLT2は、腎臓におけるグルコースの[[reabsorption/ja\|再吸収]]に関与する主要な共輸送体である。 SGLT2は初期の[[proximal tubule/ja\|近位尿細管]]に存在し、腎臓[[Glomerulus (kidney)/ja\|糸球体]]で濾過されるグルコースの80～90％の再吸収を担っている。残りのグルコース吸収のほとんどは、近位尿細管のより遠位部にある[[sodium/glucose cotransporter 1/ja\|ナトリウム/グルコース共輸送体1]]（SGLT1）によるものである。
	~~</div>~~

	<div lang="en" dir="ltr" class="mw-content-ltr">		<div lang="en" dir="ltr" class="mw-content-ltr">

Fire at 10:52, 18 February 2024

2024-02-18T10:52:40Z

← Older revision		Revision as of 19:52, 18 February 2024
Line 1:		Line 1:
	<languages />		<languages />
	~~{{Infobox gene\|Sodium/glucose cotransporter 2}}~~

	~~<div lang="en" dir="ltr" class="mw-content-ltr">~~		'''ナトリウム/グルコース共輸送体2'''（'''sodium/glucose cotransporter 2'''）（SGLT2）は、ヒトでは{{gene\|SLC5A2}}によってコードされる[[protein/ja\|タンパク質]]である。
	~~The~~ '''sodium/glucose cotransporter 2''' ~~(SGLT2) is a [[protein]] that in humans is encoded by the~~ {{gene\|SLC5A2}} ~~(solute carrier family 5 (sodium/glucose cotransporter))~~ [[~~gene~~]].
	~~</div>~~

	<div lang="en" dir="ltr" class="mw-content-ltr">		<div lang="en" dir="ltr" class="mw-content-ltr">

Fire: Created page with "{{Infobox gene|Sodium/glucose cotransporter 2}}"

2024-02-18T10:50:21Z

Created page with "{{Infobox gene|Sodium/glucose cotransporter 2}}"

New page

<languages />
{{Infobox gene|Sodium/glucose cotransporter 2}}

<div lang="en" dir="ltr" class="mw-content-ltr">
The '''sodium/glucose cotransporter 2''' (SGLT2) is a [[protein]] that in humans is encoded by the {{gene|SLC5A2}} (solute carrier family 5 (sodium/glucose cotransporter)) [[gene]].
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== Function ==
SGLT2 is a member of the [[sodium-glucose transport proteins|sodium glucose cotransporter family]], which are sodium-dependent [[glucose]] transport proteins. SGLT2 is the major cotransporter involved in glucose [[reabsorption]] in the kidney. SGLT2 is located in the early [[proximal tubule]], and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney [[Glomerulus (kidney)|glomerulus]]. Most of the remaining glucose absorption is by [[sodium/glucose cotransporter 1]] (SGLT1) in more distal sections of the proximal tubule.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== SGLT2 inhibitors for diabetes ==
{{Main|SGLT2 inhibitor}}
[[SGLT2 inhibitor]]s are also called gliflozins or flozins. They lead to a reduction in blood glucose levels, and therefore have potential use in the treatment of [[type 2 diabetes]]. Gliflozins enhance glycemic control as well as reduce [[Human body weight|body weight]] and systolic and diastolic [[blood pressure]]. The gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to euglycemic [[ketoacidosis]]. Other side effects of gliflozins include increased risk of Fournier gangrene
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== Clinical significance ==
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Mutations in this gene are also associated with [[renal glycosuria]].
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== See also ==
* [[SGLT]] Family
* [[Discovery and development of gliflozins]]
* [[Phlorizin]] — a competitive inhibitor of [[SLC5A1|SGLT1]] and [[SGLT2]]
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== References ==
{{reflist|33em}}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== Further reading ==
{{refbegin|33em}}
* {{cite journal | vauthors = van den Heuvel LP, Assink K, Willemsen M, Monnens L | title = Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) | journal = Human Genetics | volume = 111 | issue = 6 | pages = 544–7 | date = Dec 2002 | pmid = 12436245 | doi = 10.1007/s00439-002-0820-5 | s2cid = 28089635 }}
* {{cite journal | vauthors = Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D | title = Molecular analysis of the SGLT2 gene in patients with renal glucosuria | journal = Journal of the American Society of Nephrology | volume = 14 | issue = 11 | pages = 2873–82 | date = Nov 2003 | pmid = 14569097 | doi = 10.1097/01.asn.0000092790.89332.d2 | doi-access = free }}
* {{cite journal | vauthors = Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA | title = Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter | journal = The American Journal of Physiology | volume = 263 | issue = 3 Pt 2 | pages = F459-65 | date = Sep 1992 | pmid = 1415574 | doi = 10.1152/ajprenal.1992.263.3.F459}}
* {{cite journal | vauthors = Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ, Santer R | title = Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion | journal = Nephrology, Dialysis, Transplantation | volume = 23 | issue = 12 | pages = 3874–9 | date = Dec 2008 | pmid = 18622023 | doi = 10.1093/ndt/gfn386 | doi-access = free }}
* {{cite journal | vauthors = Calado J, Soto K, Clemente C, Correia P, Rueff J | title = Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria | journal = Human Genetics | volume = 114 | issue = 3 | pages = 314–6 | date = Feb 2004 | pmid = 14614622 | doi = 10.1007/s00439-003-1054-x | s2cid = 23741937 }}
* {{cite journal | vauthors = Magen D, Sprecher E, Zelikovic I, Skorecki K | title = A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria | journal = Kidney International | volume = 67 | issue = 1 | pages = 34–41 | date = Jan 2005 | pmid = 15610225 | doi = 10.1111/j.1523-1755.2005.00053.x | doi-access = free }}
* {{cite journal | vauthors = Castaneda F, Burse A, Boland W, Kinne RK | title = Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes | journal = International Journal of Medical Sciences | volume = 4 | issue = 3 | pages = 131–9 | year = 2007 | pmid = 17505558 | pmc = 1868657 | doi = 10.7150/ijms.4.131 }}
{{refend}}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
{{Solute carrier family|bg|bg0}}
{{Sodium-glucose transporter modulators}}
{{二次利用|date=18 December 2023}}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[Category:Solute carrier family]]
[[Category:Genes mutated in mice]]
</div>